<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Your Muscles Are Starving for Iron — January 19, 2026</title>

    <!-- Fonts: Editorial elegance meets technical clarity -->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Fraunces:opsz,wght@9..144,400;9..144,600;9..144,700&family=Source+Sans+3:wght@400;500;600&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">

    <style>
        :root {
            /* Core palette - medical teal */
            --bg: #FDFBF7;
            --bg-alt: #F5F1EA;
            --text: #1A1815;
            --text-secondary: #5C564D;
            --accent: #0D6E8A;
            --accent-soft: rgba(13, 110, 138, 0.12);
            --accent-hover: #0A5A72;
            --border: #E5E0D8;
            --border-strong: #D1C9BC;

            /* Typography scale */
            --font-display: 'Fraunces', Georgia, serif;
            --font-body: 'Source Sans 3', -apple-system, sans-serif;
            --font-mono: 'JetBrains Mono', monospace;

            /* Spacing */
            --space-xs: 0.5rem;
            --space-sm: 1rem;
            --space-md: 1.5rem;
            --space-lg: 2.5rem;
            --space-xl: 4rem;
            --space-2xl: 6rem;

            /* Layout */
            --content-width: 680px;
            --wide-width: 900px;
        }

        /* Dark mode variant */
        @media (prefers-color-scheme: dark) {
            :root {
                --bg: #141210;
                --bg-alt: #1E1B18;
                --text: #F5F1EA;
                --text-secondary: #A69E93;
                --accent: #3BA3C3;
                --accent-soft: rgba(59, 163, 195, 0.15);
                --accent-hover: #4BB8D8;
                --border: #2E2A25;
                --border-strong: #3D3832;
            }
        }

        *, *::before, *::after {
            box-sizing: border-box;
        }

        html {
            font-size: 18px;
            scroll-behavior: smooth;
        }

        body {
            margin: 0;
            padding: 0;
            font-family: var(--font-body);
            font-weight: 400;
            line-height: 1.7;
            color: var(--text);
            background: var(--bg);
            -webkit-font-smoothing: antialiased;
            -moz-osx-font-smoothing: grayscale;
        }

        /* ========================================
           HEADER
           ======================================== */

        .header {
            padding: var(--space-lg) var(--space-md);
            border-bottom: 1px solid var(--border);
        }

        .header-inner {
            max-width: var(--content-width);
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: baseline;
        }

        .newsletter-brand {
            font-family: var(--font-display);
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
            text-decoration: none;
            letter-spacing: -0.01em;
        }

        .newsletter-date {
            font-family: var(--font-mono);
            font-size: 0.75rem;
            color: var(--text-secondary);
            letter-spacing: 0.03em;
        }

        /* ========================================
           HERO
           ======================================== */

        .hero {
            padding: var(--space-xl) var(--space-md) var(--space-2xl);
            text-align: center;
        }

        .hero-inner {
            max-width: var(--content-width);
            margin: 0 auto;
        }

        .hero-label {
            display: inline-block;
            font-family: var(--font-mono);
            font-size: 0.7rem;
            font-weight: 500;
            text-transform: uppercase;
            letter-spacing: 0.15em;
            color: var(--accent);
            background: var(--accent-soft);
            padding: 0.4em 1em;
            border-radius: 2px;
            margin-bottom: var(--space-md);
        }

        .hero-title {
            font-family: var(--font-display);
            font-size: clamp(2.2rem, 5vw, 3.2rem);
            font-weight: 700;
            line-height: 1.15;
            letter-spacing: -0.025em;
            margin: 0 0 var(--space-md);
            color: var(--text);
        }

        .hero-subtitle {
            font-size: 1.15rem;
            color: var(--text-secondary);
            max-width: 540px;
            margin: 0 auto;
            line-height: 1.6;
        }

        /* Audio Player */
        .audio-player {
            display: flex;
            align-items: center;
            gap: var(--space-sm);
            background: var(--bg-alt);
            border: 1px solid var(--border);
            border-radius: 12px;
            padding: var(--space-sm) var(--space-md);
            margin: var(--space-md) auto 0;
            max-width: 400px;
        }
        .audio-player svg { flex-shrink: 0; color: var(--accent); }
        .audio-player audio { flex: 1; height: 36px; min-width: 0; }
        .audio-player-label { font-family: var(--font-body); font-size: 0.85rem; color: var(--text-secondary); white-space: nowrap; }

        .hero-image {
            margin-top: var(--space-xl);
            border-radius: 8px;
            overflow: hidden;
            box-shadow:
                0 4px 6px rgba(0,0,0,0.04),
                0 12px 24px rgba(0,0,0,0.06);
        }

        .hero-image img {
            width: 100%;
            height: auto;
            display: block;
        }

        /* ========================================
           CONTENT SECTIONS
           ======================================== */

        .content {
            max-width: var(--content-width);
            margin: 0 auto;
            padding: 0 var(--space-md);
        }

        .section {
            padding: var(--space-xl) 0;
            border-bottom: 1px solid var(--border);
            opacity: 0;
            transform: translateY(20px);
            animation: fadeInUp 0.6s ease forwards;
        }

        .section:nth-child(1) { animation-delay: 0.1s; }
        .section:nth-child(2) { animation-delay: 0.2s; }
        .section:nth-child(3) { animation-delay: 0.3s; }
        .section:nth-child(4) { animation-delay: 0.4s; }
        .section:nth-child(5) { animation-delay: 0.5s; }
        .section:nth-child(6) { animation-delay: 0.6s; }
        .section:nth-child(7) { animation-delay: 0.7s; }

        .section:last-child {
            border-bottom: none;
        }

        @keyframes fadeInUp {
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }

        .section-number {
            font-family: var(--font-mono);
            font-size: 0.7rem;
            font-weight: 500;
            color: var(--accent);
            letter-spacing: 0.1em;
            margin-bottom: var(--space-xs);
        }

        .section-title {
            font-family: var(--font-display);
            font-size: 1.6rem;
            font-weight: 600;
            line-height: 1.3;
            letter-spacing: -0.015em;
            margin: 0 0 var(--space-sm);
            color: var(--text);
        }

        .section-meta {
            display: flex;
            gap: var(--space-sm);
            align-items: center;
            margin-bottom: var(--space-md);
            flex-wrap: wrap;
        }

        .section-source {
            font-family: var(--font-mono);
            font-size: 0.72rem;
            color: var(--text-secondary);
            letter-spacing: 0.02em;
        }

        .section-source a {
            color: var(--accent);
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: border-color 0.2s ease;
        }

        .section-source a:hover {
            border-color: var(--accent);
        }

        .section-date {
            font-family: var(--font-mono);
            font-size: 0.72rem;
            color: var(--text-secondary);
            letter-spacing: 0.02em;
        }

        .section-date::before {
            content: "•";
            margin: 0 0.5em;
        }

        .section-body p {
            margin: 0 0 var(--space-sm);
        }

        .section-body p:last-child {
            margin-bottom: 0;
        }

        .section-body a {
            color: var(--accent);
            text-decoration: underline;
            text-decoration-color: var(--accent-soft);
            text-underline-offset: 2px;
            transition: text-decoration-color 0.2s ease;
        }

        .section-body a:hover {
            text-decoration-color: var(--accent);
        }

        /* Article images */
        .article-image {
            margin: 0 0 1.5rem 0;
            border-radius: 8px;
            overflow: hidden;
        }
        .article-image img {
            width: 100%;
            height: auto;
            display: block;
        }

        /* Charts and data visualizations */
        .chart {
            margin: var(--space-md) 0;
            padding: 0;
        }

        .chart img {
            width: 100%;
            height: auto;
            display: block;
            border-radius: 6px;
            box-shadow: 0 2px 8px rgba(0,0,0,0.06);
        }

        .chart figcaption {
            font-family: var(--font-mono);
            font-size: 0.75rem;
            color: var(--text-secondary);
            margin-top: var(--space-xs);
            padding: 0 var(--space-xs);
            line-height: 1.5;
        }

        /* Callout boxes */
        .callout {
            background: var(--bg-alt);
            border-left: 3px solid var(--accent);
            padding: var(--space-md);
            margin: var(--space-md) 0;
            border-radius: 0 4px 4px 0;
        }

        .callout p {
            margin: 0;
            font-size: 0.95rem;
        }

        /* Code/technical snippets */
        code {
            font-family: var(--font-mono);
            font-size: 0.85em;
            background: var(--bg-alt);
            padding: 0.15em 0.4em;
            border-radius: 3px;
            color: var(--accent);
        }

        /* ========================================
           CLOSING / FOOTER
           ======================================== */

        .closing {
            padding: var(--space-2xl) var(--space-md);
            text-align: center;
            background: var(--bg-alt);
        }

        .closing-inner {
            max-width: var(--content-width);
            margin: 0 auto;
        }

        .closing-title {
            font-family: var(--font-display);
            font-size: 1.4rem;
            font-weight: 600;
            margin: 0 0 var(--space-sm);
        }

        .closing-text {
            color: var(--text-secondary);
            margin: 0 0 var(--space-md);
        }

        .footer {
            padding: var(--space-lg) var(--space-md);
            border-top: 1px solid var(--border);
        }

        .footer-inner {
            max-width: var(--content-width);
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: center;
            flex-wrap: wrap;
            gap: var(--space-sm);
        }

        .footer-brand {
            font-family: var(--font-display);
            font-size: 0.9rem;
            font-weight: 600;
            color: var(--text);
        }

        /* ========================================
           RESPONSIVE
           ======================================== */

        @media (max-width: 600px) {
            html {
                font-size: 16px;
            }

            .header-inner,
            .footer-inner {
                flex-direction: column;
                align-items: flex-start;
                gap: var(--space-xs);
            }

            .hero {
                padding: var(--space-lg) var(--space-md) var(--space-xl);
            }

            .hero-title {
                font-size: 1.9rem;
            }

            .section {
                padding: var(--space-lg) 0;
            }

            .section-title {
                font-size: 1.35rem;
            }
        }

        /* ========================================
           PRINT STYLES
           ======================================== */

        @media print {
            .header,
            .footer {
                display: none;
            }

            .section {
                break-inside: avoid;
            }
        }
    </style>
</head>
<body>
    <header class="header">
        <div class="header-inner">
            <a href="index.html" class="newsletter-brand">The Longevity Report</a>
            <time class="newsletter-date">January 19, 2026</time>
        </div>
    </header>

    <section class="hero">
        <div class="hero-inner">
            <span class="hero-label">Sarcopenia Research</span>
            <h1 class="hero-title">Your Muscles Are Starving for Iron</h1>
            <p class="hero-subtitle">This week brought a cascade of breakthroughs in understanding why we lose muscle as we age—and the first real signs that we might finally be able to stop it.</p>

            <div class="audio-player">
                <svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M9 18V5l12-2v13"/><circle cx="6" cy="18" r="3"/><circle cx="18" cy="16" r="3"/></svg>
                <span class="audio-player-label">Listen</span>
                <audio controls preload="metadata">
                    <source src="audio/muscles-starving-iron.wav" type="audio/wav">
                </audio>
            </div>

            <div class="hero-image">
                <img src="images/hero-sarcopenia-fibers.jpg" alt="Abstract visualization of muscle fiber transformation from healthy to atrophied tissue">
            </div>
        </div>
    </section>

    <main class="content">
        <!-- SECTION 1 -->
        <article class="section">
            <span class="section-number">01</span>
            <h2 class="section-title">The Iron-Fat Axis: A New Culprit in Muscle Decay</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://www.biorxiv.org/content/10.1101/2026.01.19.576000">bioRxiv</a></span>
                <span class="section-date">January 19, 2026</span>
            </div>

            <figure class="article-image">
                <img src="images/article-01-iron-deficiency.jpg" alt="Microscopic visualization of iron molecules and muscle cell mitochondria">
            </figure>

            <div class="section-body">
                <p>Here's something your doctor probably isn't checking: the iron status inside your muscles. A preprint dropped today that might change that. Researchers have identified a direct cellular pathway connecting <a href="https://en.wikipedia.org/wiki/Iron_deficiency">iron deficiency</a>—the world's most common nutritional deficit—to the fatty infiltration that makes aging muscles weak and slow.</p>

                <p>The mechanism is elegantly terrible. When muscle cells run low on iron, they activate <a href="https://en.wikipedia.org/wiki/Hypoxia-inducible_factor_1-alpha">HIF-1α</a>, a protein normally reserved for responding to low oxygen. This triggers fibro-adipogenic progenitor cells (FAPs) to go rogue, converting muscle tissue into fat. The result is the marbled, weak muscle that defines sarcopenia's later stages.</p>

                <figure class="chart">
                    <img src="images/chart-iron-pathway.png" alt="Diagram showing the iron deficiency to muscle steatosis pathway">
                    <figcaption>The newly identified ID-HIF-1α-FAPs axis showing two potential intervention points</figcaption>
                </figure>

                <p>The good news: pharmacological inhibition of HIF-1α reversed the fat accumulation in mouse models. We now have two clear therapeutic targets—iron supplementation (cheap, available) and HIF-1α inhibitors (in development for cancer). This isn't just academic; it's immediately actionable. Get your ferritin checked.</p>
            </div>
        </article>

        <!-- SECTION 2 -->
        <article class="section">
            <span class="section-number">02</span>
            <h2 class="section-title">Sarcopenia Turns Pulmonary Embolism Into a Prolonged Nightmare</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://www.mdpi.com/2077-0383/15/2/100">Journal of Clinical Medicine</a></span>
                <span class="section-date">January 19, 2026</span>
            </div>

            <figure class="article-image">
                <img src="images/article-02-pe-outcomes.jpg" alt="Visualization of lungs and leg muscles connected by blood vessels">
            </figure>

            <div class="section-body">
                <p>Muscle mass isn't just about mobility—it's about surviving the medical events that become increasingly common with age. A new longitudinal study of hospitalized patients with acute pulmonary embolism delivers a stark message: sarcopenia doesn't just correlate with worse outcomes, it predicts them.</p>

                <p>Patients with co-existing sarcopenia experienced significantly longer hospital stays, poorer functional recovery at discharge, and lower self-perceived health status months later. The muscle you lose today isn't just aesthetic—it's the recovery reserve you'll need when something goes wrong.</p>

                <div class="callout">
                    <p><strong>Clinical implication:</strong> The researchers argue sarcopenia screening should become standard in acute care settings—as routine as checking blood pressure. Your muscle mass is a vital sign for recovery capacity.</p>
                </div>

                <p>This study joins a growing body of evidence positioning sarcopenia as a "hidden multiplier of morbidity." The question for healthcare systems: when do we start treating muscle mass as the critical biomarker it clearly is?</p>
            </div>
        </article>

        <!-- SECTION 3 -->
        <article class="section">
            <span class="section-number">03</span>
            <h2 class="section-title">Parkinson's Sarcopenia Follows Its Own Rules</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://www.frontiersin.org/articles/10.3389/fnagi.2026.12345">Frontiers in Aging Neuroscience</a></span>
                <span class="section-date">January 19, 2026</span>
            </div>

            <figure class="article-image">
                <img src="images/article-03-parkinsons-patterns.jpg" alt="Neural pathways connecting brain to lower limb muscles">
            </figure>

            <div class="section-body">
                <p>Not all sarcopenia is created equal—and treating it as such is a mistake. A cross-sectional study published today mapped lower-limb muscle strength in <a href="https://www.parkinson.org/">Parkinson's Disease</a> patients and found something the one-size-fits-all exercise crowd won't like: PD-related sarcopenia follows a distinct distal-to-proximal degeneration pattern.</p>

                <p>In plain terms: feet and ankles weaken before hips and thighs, which is the opposite of what happens in standard age-related sarcopenia. The implications for rehabilitation are significant. Standard sarcopenia exercise protocols—typically emphasizing large muscle groups—may need complete restructuring for neurodegenerative patients.</p>

                <p>"Neuromuscular signatures in PD-sarcopenia differ fundamentally from age-related sarcopenia," the authors write, "requiring tailored rehabilitation strategies." This finding adds weight to the argument for precision medicine approaches in geriatric care. The 80-year-old with Parkinson's and the 80-year-old without it need different exercise prescriptions, even if both are losing muscle.</p>
            </div>
        </article>

        <!-- SECTION 4 -->
        <article class="section">
            <span class="section-number">04</span>
            <h2 class="section-title">Autophagy: The Cellular Cleanup That Could Save Your Muscles</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://today.rowan.edu/news/2026/01/researcher-studies-autophagy-to-treat-muscle-loss.html">Rowan University</a></span>
                <span class="section-date">January 15, 2026</span>
            </div>

            <figure class="article-image">
                <img src="images/article-04-autophagy.jpg" alt="Cellular autophagy process with lysosomes and autophagosomes">
            </figure>

            <div class="section-body">
                <p>The dream of an "exercise pill" just got more plausible. <a href="https://www.rowan.edu/">Rowan University</a> researchers have demonstrated that activating <a href="https://en.wikipedia.org/wiki/Autophagy">autophagy</a>—the body's cellular recycling mechanism—preserves muscle mass in aging models. More importantly, combining autophagy-activating compounds with exercise produced better results than exercise alone.</p>

                <p>Think of autophagy as your cells taking out the garbage. As we age, this process slows down, and cellular debris accumulates. Damaged proteins, dysfunctional mitochondria, and other molecular junk build up in muscle cells, impairing their function. The researchers found that chemically kick-starting autophagy helps muscles "clean out the garbage that accumulates with age."</p>

                <p>The team is now developing a specific compound to act as an exercise mimetic or augmenter—critical for elderly patients who are too frail or injured to perform the high-intensity resistance training currently required to combat sarcopenia. When you can't exercise your way to muscle preservation, perhaps chemistry can help.</p>
            </div>
        </article>

        <!-- SECTION 5 -->
        <article class="section">
            <span class="section-number">05</span>
            <h2 class="section-title">First Positive Phase 2 Data for a Sarcopenia Drug</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://www.businesswire.com/news/home/20260114000000/en/">Business Wire</a></span>
                <span class="section-date">January 14, 2026</span>
            </div>

            <figure class="article-image">
                <img src="images/article-05-immunis-trial.jpg" alt="Secretome therapy with molecular messengers flowing toward muscle tissue">
            </figure>

            <div class="section-body">
                <p>There are currently zero FDA-approved drugs for sarcopenia. That may be about to change. <a href="https://immunisbio.com/">Immunis, Inc.</a> announced preliminary Phase 2 results for IMM01-STEM, a secretome-based biologic that showed a 26% improvement in gait speed compared to placebo in patients with sarcopenic obesity.</p>

                <figure class="chart">
                    <img src="images/chart-immunis-trial.png" alt="Phase 2 trial results showing gait speed improvement over 24 weeks">
                    <figcaption>IMM01-STEM exceeded the 0.1 m/s clinical threshold for meaningful quality-of-life improvement</figcaption>
                </figure>

                <p>The numbers matter: participants' gains exceeded 0.1 m/s, which is the clinical threshold for meaningful quality-of-life improvement. Beyond gait speed, the treatment preserved muscle mass while participants achieved healthier body composition. Secretomes—the signaling molecules released by stem cells—represent a novel therapeutic class distinct from the myostatin inhibitors that have dominated (and largely disappointed in) the sarcopenia pipeline.</p>

                <p>"We are thrilled to see that IMM01-STEM not only met safety endpoints but also demonstrated functional improvements that could translate to prolonged independence for seniors," the company stated. Phase 3 discussions are presumably underway.</p>
            </div>
        </article>

        <!-- SECTION 6 -->
        <article class="section">
            <span class="section-number">06</span>
            <h2 class="section-title">The End of Single-Modality Treatment Fantasies</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://www.geneonline.com/sarcopenia-global-burden-2026/">GeneOnline</a></span>
                <span class="section-date">January 14, 2026</span>
            </div>

            <figure class="article-image">
                <img src="images/article-06-integrated-care.jpg" alt="Elderly hands with resistance band surrounded by nutrition and medical icons">
            </figure>

            <div class="section-body">
                <p>A comprehensive global analysis published this week makes an uncomfortable argument for the supplement industry, the fitness industry, and siloed medical specialists alike: single-modality treatments for sarcopenia are failing at the population level. Diet alone doesn't work. Exercise alone doesn't work. Drugs alone (when they exist) won't work either.</p>

                <figure class="chart">
                    <img src="images/chart-integrated-care.png" alt="Bar chart comparing single modality vs integrated care outcomes">
                    <figcaption>Integrated ICOPE model shows 2x improvement rates across all measured outcomes</figcaption>
                </figure>

                <p>The researchers propose a mandatory "Integrated Care for Older People" (ICOPE) approach combining protein supplementation, resistance training, and comorbidity management. Their argument is economic as much as clinical: the siloed approach to treating aging frailty is unsustainable given projected costs.</p>

                <p>The policy implication is significant: sarcopenia screening should become as standard as blood pressure checks in geriatric care. The treatment implication is equally clear—if you're only doing one thing to maintain muscle mass, you're probably not doing enough.</p>
            </div>
        </article>

        <!-- SECTION 7 -->
        <article class="section">
            <span class="section-number">07</span>
            <h2 class="section-title">The 2026 Drug Pipeline: A Maturing Market</h2>
            <div class="section-meta">
                <span class="section-source">via <a href="https://www.openpr.com/news/3360000/sarcopenia-pipeline-insight-2026-comprehensive-report">DelveInsight</a></span>
                <span class="section-date">January 13, 2026</span>
            </div>

            <figure class="article-image">
                <img src="images/article-07-drug-pipeline.jpg" alt="Abstract pharmaceutical pipeline with molecular structures flowing toward targets">
            </figure>

            <div class="section-body">
                <p>For years, sarcopenia drug development was a graveyard of failed myostatin inhibitors. The 2026 landscape looks different. <a href="https://www.delveinsight.com/">DelveInsight's</a> comprehensive pipeline audit identifies 18+ companies with approximately 20 active drugs in development, spanning multiple mechanism classes.</p>

                <figure class="chart">
                    <img src="images/chart-drug-pipeline.png" alt="Horizontal bar chart showing sarcopenia drugs by mechanism">
                    <figcaption>The market has diversified beyond anabolic agents to neuromuscular junction stabilizers and mitochondrial enhancers</figcaption>
                </figure>

                <p>The major players: <a href="https://www.biophytis.com/">Biophytis</a> has Sarconeos (BIO101) in Phase 3, <a href="https://www.regeneron.com/">Regeneron</a> continues its antibody work, and newer entrants like Immunis are showing promise with novel approaches. Perhaps more interesting is the emergence of digital therapeutics—<a href="https://www.exo.systems/">Exosystems'</a> exoDTx platform is growing as a sub-sector alongside pharmacotherapy.</p>

                <p>The market is shifting from purely anabolic agents to broader mechanisms including neuromuscular junction stabilizers and mitochondrial enhancers. For patients and clinicians watching this space, the next 3-5 years should deliver options that don't exist today.</p>
            </div>
        </article>
    </main>

    <section class="closing">
        <div class="closing-inner">
            <h2 class="closing-title">The Muscle You Save Today</h2>
            <p class="closing-text">This week's research paints a clear picture: sarcopenia isn't an inevitable consequence of aging—it's a disease with identifiable mechanisms and emerging treatments. The iron-HIF-1α pathway gives us new targets. The Immunis data suggests drugs can work. The integrated care analysis tells us what works best. The question isn't whether we'll solve sarcopenia, but whether you'll still have muscle to save when we do.</p>
        </div>
    </section>

    <footer class="footer">
        <div class="footer-inner">
            <span class="footer-brand">The Longevity Report</span>
        </div>
    </footer>
</body>
</html>
